William Looney

Autumn is a good time to present our annual post on how well the industry is doing in harvesting value for shareholders. Our diverse list of 24 companies, drawn from Big Pharma to the established biotechs, presents a similarly mixed picture on returns: smaller firms with a distinct customer base and tight oversight of costs are by and large proving more adept at delivering the strong growth that investors still expect from this business.

This month's feature by Ben Comer highlights what's behind the new Corporate Integrity Agreement (CIA) imposed on GSK by theHHS Office of Inspector-General to compensate for a long list of marketing and pricing malfeasances

Pharm Exec's 2012 roster of Emerging Leaders-our sixth to date-is not only a way to recognize a few individuals who've made a difference in their organizations. It also serves as a barometer to track larger changes in the workplace.

Mastery of the clinical trial process has become essential to positioning new therapies for leadership in an increasingly crowded-and lengthy-race to registration.

In a wake up call to this year's Emerging Leaders a group of St. Joseph's Business School Health Management alumni say time has no limit on surprises-change for pharma is here and its good.

Multidrug resistant [MDR] TB is the front line in the global battle against infectious disease. It accounts for more than 5 per cent of new cases of TB, which itself takes more than 2 million lives per year – a death toll second only to HIV.

As the old Broadway song goes, June is busting out all over-and true to the season this month's issue stretches the seams with content that ranges from the sublime to the ridiculous.

CBI conference highlights three turnaround strategies to plug the gaps in patient adherence.

The industry's reputation as a growth industry no one wants to pay for is more secure than ever, writes Pharm Exec Editor William Looney.

Data has become as important as the drug in driving success in healthcare.

Broaden your industry exposure. Think beyond yourself... Timely advice from this year's HBA Woman of the Year, Carolyn Buck Luce.

IP must adapt to new ways of extracting value from assets the industry never knew it had, writes William Looney.

India's most prominent scientist, Dr R.A. Mashelkar, President of the Global Research Alliance, on delivering medicines profitably but cheaply to low income countries.

With growth as its guiding light, Novartis has big plans for the emerging markets. Pharm Exec sits down with CEO Joe Jimenez to understand what it will take the company to best the competition.

One of the key reputational assets of Big Pharma is the patient assistance program [PAP], which provides patented innovative medicines to needy patients for free or at a nominal charge – it’s the industry’s own branded version of the social safety net

Pharm Exec's latest EAB meeting offered a frank exchange on this magazine's digital future.

Following the premise that good news needs to be shared, Pharm Exec is proud to announce that one of our sister Advanstar publications, Medical Economics, has been selected as Media Brand of the Year by Medical Marketing and Media (MM&M) magazine.

The Healthcare Businesswomen’s Association (HBA) has announced that its 2012 Woman of the Year (WOTY) is Carolyn Buck Luce, global pharmaceutical sector leader at Ernst & Young.

A new generation of products for inflammatory disease is coming forward, promising better promise and possibly a cure.

William Looney looks at the three P’s of effectiveness research: PCORI, Priorities, and Politics

Pharm Exec sits down with CEO Atsushi Nagahisa to explore how culture can maximize the value of an inherited portfolio

Keeping skittish patients on their medicines ought to be a strategic priority for Big Pharma - but is it? Pharm Exec convenes an expert round table to examine how best to make progress and agree on some practical steps for incorporation in the campaign agenda.

The gap in perception is one of industry's biggest problems because it adds ballast to the idea that medicines are just a simple procurement item, writes William Looney.

If high prices that lower access are attributable to a flawed R&D model, can industry embrace delivering better results at lower costs.

P. Roy Vagelos, MD, Chairman Emeritus, Merck

Pharm Exec celebrates its 30th birthday with a gathering of 30 of the industry's key influencers of the last three decades.

Napoleone Ferrara, MD, PhD, Research Fellow, Genentech

Peter Piot, MD, Director, London School of Hygiene and Tropical Medicine

Sir Martin Sorrell, CEO, WPP

Yasuchika Hasegawa, President & CEO, Takeda Pharmaceutical Co.